Complete response to talazoparib in patient with pancreatic adenocarcinoma harboring somatic PALB2 mutation: A case report and literature review

被引:1
|
作者
Kachmazov, Andrei [1 ]
Bolotina, Larisa [1 ]
Kornietskaya, Anna [1 ]
Kuznetsova, Olesya [2 ,3 ]
Ivanov, Maxim [3 ]
Fedenko, Alexander [1 ]
机构
[1] Minist Hlth Russian Federat, P Hertsen Moscow Oncol Clin Res Inst, Branch Natl Med Res Radiol Ctr, Moscow, Russia
[2] NN Blokhin Natl Med Res Ctr Oncol Minist Hlth Russ, Fed State Budgetary Inst, Moscow, Russia
[3] Atlas Oncodiagnost LLC, RnD Dept, Moscow, Russia
来源
FRONTIERS IN ONCOLOGY | 2022年 / 12卷
关键词
pancreatic cancer; PDAC; talazoparib; PARP inhibitors; PARPi; PALB2; molecular profiling; precision oncology; CANCER; GEMCITABINE; TRIAL;
D O I
10.3389/fonc.2022.953908
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PARP inhibitors have recently emerged as a maintenance treatment option for metastatic pancreatic cancer patients with germline BRCA mutations. However, the possibility of PARP-inhibitor use as a standalone-targeted therapy for patients with various homologous repair pathway alterations remains mostly undetermined. Here we report a clinical case of a 56-year-old woman with pancreatic ductal adenocarcinoma harboring a somatic PALB2 mutation. Following disease progression after 10 cycles of FOLFIRINOX chemotherapy and two cycles of second-line gemcitabine, she was switched to talazoparib and achieved a complete clinical response after 25 months of treatment. The patient remains alive without clinical or radiological signs of disease progression three years after the start of talazoparib with no targeted therapy-related toxicities. This case highlights the role of broad molecular profiling as a window of opportunity to achieve a durable response for selected pancreatic cancer patients while pinpointing our gaps in understanding the whole picture of management of these patients since a new puzzle element represented by PARP inhibitors was introduced to clinical practice.
引用
收藏
页数:6
相关论文
共 50 条
  • [1] Case Report: Effectiveness of Targeted Treatment in a Patient With Pancreatic Cancer Harboring PALB2 Germline Mutation and KRAS Somatic Mutation
    Wu, Wei
    Liu, Yu
    Jin, Yuzhi
    Liu, Lulu
    Guo, Yixuan
    Xu, Mian
    Hao, Qing
    Li, Dazhi
    Fang, Weijia
    Zhang, Aibin
    Zhao, Peng
    FRONTIERS IN MEDICINE, 2022, 8
  • [2] Leptomeningeal carcinomatosis in a patient with PALB2-mutated pancreatic adenocarcinoma: A case report and review of the literature
    Walker, Dylan D.
    Kubas, Benjamin G.
    Clifton, Guy T.
    Burris, Jason K.
    Rendo, Matthew J.
    CURRENT PROBLEMS IN CANCER: CASE REPORTS, 2023, 11
  • [3] Pathogenic PALB2 mutation in metastatic pancreatic adenocarcinoma and neuroendocrine tumour: A case report
    Chan, David
    Clarke, Stephen
    Gill, Anthony J.
    Chantrill, Lorraine
    Samra, Jas
    Li, Bob T.
    Barnes, Tristan
    Nahar, Kazi
    Pavlakis, Nick
    MOLECULAR AND CLINICAL ONCOLOGY, 2015, 3 (04) : 817 - 819
  • [4] Pancreatic Adenocarcinoma in the Pregnant Patient: A Case Report and Literature Review
    Kakoza, Rose M.
    Vollmer, Charles M., Jr.
    Stuart, Keith E.
    Takoudes, Tamara
    Hanto, Douglas W.
    JOURNAL OF GASTROINTESTINAL SURGERY, 2009, 13 (03) : 535 - 541
  • [5] Pleomorphic/solid lobular carcinoma of male breast with PALB2 germline mutation: case report and literature review
    Rogges, Evelina
    Corati, Tiberio
    Amato, Michelina
    Campagna, Domenico
    Farro, Juliette
    De Toffol, Simona
    Fortunato, Lucio
    Costarelli, Leopoldo
    PATHOLOGICA, 2024, 116 (01) : 62 - 68
  • [6] Long-term response in advanced pancreatic adenocarcinoma - a case report and literature review
    Daball, Paola Cura
    Troeger, Hanno
    Daum, Severin
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2022, 60 (10): : 1510 - 1516
  • [7] Pancreatic Adenocarcinoma in the Pregnant Patient: A Case Report and Literature Review
    Rose M. Kakoza
    Charles M. Vollmer Jr.
    Keith E. Stuart
    Tamara Takoudes
    Douglas W. Hanto
    Journal of Gastrointestinal Surgery, 2009, 13 : 535 - 541
  • [8] Molecular Targeting of a BRAF Mutation in Pancreatic Ductal Adenocarcinoma: Case Report and Literature Review
    Seghers, An-Katrien
    Cuyle, Pieter-Jan
    Van Cutsem, Eric
    TARGETED ONCOLOGY, 2020, 15 (03) : 407 - 410
  • [9] Pathological complete response in a patient with locally advanced pancreatic adenocarcinoma treated with neoadjuvant gemcitabine and S-1: a case report and literature review
    Hua, Surong
    Gao, Junyi
    Xu, Qiang
    Hong, Xiafei
    Wu, Wenming
    GLAND SURGERY, 2022, 11 (02) : 494 - 503
  • [10] Retrospective Survival Analysis of Patients With Resected Pancreatic Ductal Adenocarcinoma and a Germline BRCA or PALB2 Mutation
    Yu, Shun
    Agarwal, Parul
    Mamtani, Ronac
    Symecko, Heather
    Spielman, Kelsey
    O'Hara, Mark
    O'Dwyer, Peter J.
    Schneider, Charles
    Teitelbaum, Ursina
    Nathanson, Katherine L.
    Domchek, Susan M.
    Reiss, Kim A.
    JCO PRECISION ONCOLOGY, 2019, 3 : 1 - 11